Top

Published in:

Open Access 01-10-2019 | NSCLC | Original Research Article

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin^®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Authors: Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, Manuela Zereu, Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara

Published in: BioDrugs | Issue 5/2019

Abstract

Background

PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin^®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC).

Methods

In this double-blind, parallel-group study, we recruited patients from 159 centers in 27 countries. Participants were randomized 1:1 to receive PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin on day 1 of each 21-day cycle for 4–6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study. Randomization was stratified by region, sex, and smoking history. The primary endpoint was objective response rate (ORR) in accordance with RECIST 1.1, based on responses achieved by week 19 and confirmed by week 25.

Results

Between 21 May 2015 and 14 November 2016, 719 patients were randomized to the PF-06439535 group (n = 358) or the bevacizumab-EU group (n = 361). As of data cutoff for analysis of the primary endpoint (8 May 2017), 45.3% (95% confidence interval [CI] 40.01–50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40–49.89) of patients in the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25. The unstratified ORR risk ratio was 1.015 (95% CI 0.863–1.193; 90% CI 0.886–1.163), and the unstratified ORR risk difference was 0.653% (95% CI − 6.608 to 7.908); all three CIs fell within pre-specified equivalence margins. Using final data after study completion (22 December 2017), no notable differences in progression-free survival or overall survival were observed between the groups. The most frequently reported grade 3 or higher treatment-emergent adverse events were hypertension, neutropenia, and anemia. There were no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity across treatment groups.

Conclusion

Among patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-EU in terms of efficacy. Safety profiles for the two treatments were comparable.

Trial Registration

ClinicalTrials.gov, NCT02364999.

Funding

Pfizer.

Available only for authorised users

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76. https://doi.org/10.1038/nm0603-669.CrossRefPubMed

Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–80. https://doi.org/10.1200/jco.2002.10.088.CrossRefPubMed

Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.CrossRefPubMed

Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001;2:667–73. https://doi.org/10.1016/s1470-2045(01)00556-3.CrossRefPubMed

Genentech Inc. Avastin prescribing information. 2018 (last update June 2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125085s323lbl.pdf. Accessed 30 Apr 2019.

Roche Registration GmbH. Summary of product characteristics: Avastin. 2018 (last update 31 August 2018). https://www.ema.europa.eu/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 30 Apr 2019.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42. https://doi.org/10.1056/nejmoa032691.CrossRefPubMed

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50. https://doi.org/10.1056/nejmoa061884.CrossRefPubMed

Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43. https://doi.org/10.1056/nejmoa1309748.CrossRefPubMedPubMedCentral

10.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer. Version 4-2019. 2019 (last update 29 April 2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 30 Apr 2019.

11.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237. https://doi.org/10.1093/annonc/mdy275.CrossRefPubMed

12.

Monk BJ, Lammers PE, Cartwright T, Jacobs I. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. Pharmaceuticals (Basel). 2017;10:19. https://doi.org/10.3390/ph10010019.CrossRef

13.

European Medicines Agency. Guideline on similar biological medicinal products. 2014 (last update 23 October 2014). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 30 Apr 2019.

14.

US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015 (last update April 2015). https://www.fda.gov/media/82647/download. Accessed 9 May 2019.

15.

World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 (last update 23 October 2009). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 30 Apr 2019.

16.

QuintilesIMS. The impact of biosimilar competition in Europe. 2017 (last update 5 May 2017). https://ec.europa.eu/docsroom/documents/23102/attachments/1/translations/en/renditions/pdf. Accessed 30 Apr 2019.

17.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology Statement: biosimilars in oncology. J Clin Oncol. 2018;36:1260–5. https://doi.org/10.1200/jco.2017.77.4893.CrossRefPubMed

18.

Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1:e000142. https://doi.org/10.1136/esmoopen-2016-000142.CrossRefPubMed

19.

Pfizer Europe MA EEIG. Zirabev summary of product characteristics. 2019 (last update 16 April 2019). https://www.ema.europa.eu/en/documents/product-information/zirabev-epar-product-information_en.pdf. Accessed 7 May 2019.

20.

Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, et al. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab. Regul Toxicol Pharmacol. 2018;95:236–43. https://doi.org/10.1016/j.yrtph.2018.03.020.CrossRefPubMed

21.

Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77:839–46. https://doi.org/10.1007/s00280-016-3001-2.CrossRefPubMedPubMedCentral

22.

Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

23.

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. https://doi.org/10.1097/jto.0b013e31812f3c1a.CrossRefPubMed

24.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

25.

Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26.CrossRefPubMed

26.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76:362–7. https://doi.org/10.1016/j.lungcan.2011.12.005.CrossRefPubMed

27.

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91. https://doi.org/10.1200/jco.2004.11.022.CrossRefPubMed

28.

European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 (last update 18 December 2014). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 30 Apr 2019.

29.

European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. 2012 (last update 30 May 2012). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 30 Apr 2019.

30.

US Food and Drug Administration. Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018 (last update December 2018). https://www.fda.gov/media/71195/download. Accessed 30 Apr 2019.

31.

Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019;25:2088–95. https://doi.org/10.1158/1078-0432.ccr-18-2702.CrossRefPubMed

32.

Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017;317:37–47. https://doi.org/10.1001/jama.2016.18305.CrossRefPubMed

33.

Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4:e350–61. https://doi.org/10.1016/s2352-3026(17)30106-0.CrossRefPubMed

34.

Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5:e543–53. https://doi.org/10.1016/s2352-3026(18)30157-1.CrossRefPubMed

35.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97. https://doi.org/10.1200/jco.2004.08.163.CrossRefPubMed

36.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/nejmoa1507643.CrossRefPubMedPubMedCentral

37.

Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18:917–28. https://doi.org/10.1016/s1470-2045(17)30434-5.CrossRefPubMed

38.

von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19:987–98. https://doi.org/10.1016/s1470-2045(18)30241-9.CrossRef

39.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/nejmoa1716948.CrossRefPubMed

40.

Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12:599–610. https://doi.org/10.1007/s11523-017-0518-1.CrossRefPubMedPubMedCentral

41.

Amgen Inc. Mvasi (bevacizumab-awwb) prescribing information. 2017 (last update September 2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761028s000lbl.pdf. Accessed 30 Apr 2019.

42.

Amgen Europe B.V. Mvasi summary of product characteristics. 2018 (last update 10 April 2019). https://www.ema.europa.eu/documents/product-information/mvasi-epar-product-information_en.pdf. Accessed 30 Apr 2019.

Title: PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Authors: Niels Reinmuth
Maciej Bryl
Igor Bondarenko
Kostas Syrigos
Vladimir Vladimirov
Manuela Zereu
Angel H. Bair
Fiona Hilton
Katherine Liau
Kazuo Kasahara
Publication date: 01-10-2019
Publisher: Springer International Publishing
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Bevacizumab
Published in: BioDrugs / Issue 5/2019
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-019-00363-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin^®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Abstract

Background

Methods

Results

Conclusion

Trial Registration

Funding

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial Registration

Funding

Please log in to get access to this content

Other articles of this Issue 5/2019

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis

Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?

Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis